On January 10, 2015 Urology Times convened an expert panel to examine the criteria that constitute a gold standard for the treatment of male lower urinary tract symptoms (LUTS), or benign prostatic hyperplasia (BPH).
Hormone therapy plus current treatments improves survival in prostate cancer
March 23rd 2023Darolutamide increased overall survival compared to placebo in the overall patient population and patients with high-volume, high-risk mHSPC as well as in patients with low-risk metastatic hormone-sensitive prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512